HER2

Summary

Gene Symbol: HER2
Description: erb-b2 receptor tyrosine kinase 2
Alias: CD340, HER-2, HER-2/neu, HER2, MLN 19, NEU, NGL, TKR1, receptor tyrosine-protein kinase erbB-2, c-erb B2/neu protein, herstatin, human epidermal growth factor receptor 2, metastatic lymph node gene 19 protein, neuro/glioblastoma derived oncogene homolog, neuroblastoma/glioblastoma derived oncogene homolog, p185erbB2, proto-oncogene Neu, proto-oncogene c-ErbB-2, tyrosine kinase-type cell surface receptor HER2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2, v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
Species: human
Products:     HER2

Top Publications

  1. Cho H, Mason K, Ramyar K, Stanley A, Gabelli S, Denney D, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421:756-60 pubmed
    b>HER2 (also known as Neu, ErbB2) is a member of the epidermal growth factor receptor (EGFR; also known as ErbB) family of receptor tyrosine kinases, which in humans includes HER1 (EGFR, ERBB1), HER2, HER3 (ERBB3) and HER4 (ERBB4)...
  2. Tapia C, Glatz K, Novotny H, Lugli A, Horcic M, Seemayer C, et al. Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol. 2007;20:192-8 pubmed
    ..Such tumor entities should be carefully evaluated for a possible utility of trastuzumab treatment. ..
  3. Andersson U, Schwartzbaum J, Wiklund F, Sjöström S, Liu Y, Tsavachidis S, et al. A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. Acta Oncol. 2010;49:767-75 pubmed publisher
    ..Further studies are required to reinvestigate these findings and evaluate the functional significance. ..
  4. Saglam S, Suzme R, Gurdol F. Serum tumor necrosis factor-alpha and interleukin-2 concentrations in newly diagnosed ERBB2 (HER2/neu) positive breast cancer patients. Int J Biol Markers. 2009;24:142-6 pubmed
    ..Overexpression of ERBB2 (c-erb-b2; formerly HER2/neu), which is a member of the epidermal growth receptor family, is associated with involvement of lymph nodes, ..
  5. Ingold Heppner B, Behrens H, Balschun K, Haag J, Krüger S, Becker T, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer. 2014;111:1977-84 pubmed publisher
    Anti-HER2/neu therapy is well-established in breast and gastric carcinoma. The increased understanding of this pathway led to the identification of new promising drugs in addition to trastuzumab, offering further perspectives...
  6. Lerdrup M, Bruun S, Grandal M, Roepstorff K, Kristensen M, Hommelgaard A, et al. Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus. Mol Biol Cell. 2007;18:3656-66 pubmed
    ..Altogether, we suggest that geldanamycin leads to C-terminal cleavage of ErbB2, which releases the receptor from a retention mechanism and causes endocytosis and lysosomal degradation of ErbB2. ..
  7. Fijołek J, Wiatr E, Rowinska Zakrzewska E, Giedronowicz D, Langfort R, Chabowski M, et al. p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer. Int J Biol Markers. 2006;21:81-7 pubmed
    The aim of the study was to investigate a relation between p53 and HER2/neu expression in resected lung tumors and the response of those tumors to neoadjuvant chemotherapy...
  8. Ghayad S, Vendrell J, Ben Larbi S, Dumontet C, Bieche I, Cohen P. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer. 2010;126:545-62 pubmed publisher
    ..In conclusion, the combination of MAPK and PI3K inhibitors represents a promising strategy to overcome endocrine therapy resistance in ER+ breast cancer patients. ..
  9. Haslekås C, Breen K, Pedersen K, Johannessen L, Stang E, Madshus I. The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane. Mol Biol Cell. 2005;16:5832-42 pubmed

More Information

Publications249 found, 100 shown here

  1. Lang J, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, et al. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat. 2009;113:501-7 pubmed publisher
    ..0 CTC per CTC positive patient (range 1-22). HER2 status was the sole primary tumor characteristic that reliably predicted the presence of CTCs (P = 0...
  2. Papadopoulou E, Tripsianis G, Anagnostopoulos K, Tentes I, Kakolyris S, Galazios G, et al. Significance of serum tumor necrosis factor-alpha and its combination with HER-2 codon 655 polymorphism in the diagnosis and prognosis of breast cancer. Int J Biol Markers. 2010;25:126-35 pubmed
    ..The present study was conducted to clarify the diagnostic and prognostic significance of TNF-alpha and its combination with HER-2 Ile655Val SNP in breast cancer...
  3. Sun T, Aceto N, Meerbrey K, Kessler J, Zhou C, Migliaccio I, et al. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011;144:703-18 pubmed publisher
    ..PTPN12 suppresses transformation by interacting with and inhibiting multiple oncogenic tyrosine kinases, including HER2 and EGFR...
  4. Saghatchian M, Guepratte S, Hacene K, Neumann R, Floiras J, Pichon M. Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int J Biol Markers. 2004;19:14-22 pubmed
    ..To determine the clinical correlations and prognostic value of serum HER-2 (sHER-2) before and after primary breast cancer treatment...
  5. Hendriks B, Orr G, Wells A, Wiley H, Lauffenburger D. Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells. J Biol Chem. 2005;280:6157-69 pubmed
    b>HER2, a member of the epidermal growth factor receptor (EGFR) tyrosine kinase family, functions as an accessory EGFR signaling component and alters EGFR trafficking by heterodimerization...
  6. Dragowska W, Warburton C, Yapp D, Minchinton A, Hu Y, Waterhouse D, et al. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Mol Cancer Res. 2004;2:606-19 pubmed
    The effects of HER-2/neu overexpression on the tumor microenvironment in an aggressive breast cancer xenograft model were investigated...
  7. Matsubara H, Yamada Y, Naruse K, Nakamura K, Aoki S, Taki T, et al. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization. Oncol Rep. 2008;19:57-63 pubmed
    Analysis of HER-2/neu expression in invasive bladder carcinoma was performed in order to evaluate the potential for molecular targeted therapy targeting HER-2...
  8. Pedersen N, Madshus I, Haslekås C, Stang E. Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent. Mol Cancer Res. 2008;6:491-500 pubmed publisher
  9. Burris H, Rugo H, Vukelja S, Vogel C, Borson R, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29:398-405 pubmed publisher
    ..activity of trastuzumab with targeted delivery of a potent antimicrotubule agent, DM1, to human epidermal growth factor receptor 2 (HER2)-overexpressing cancer cells...
  10. Simon R, Atefy R, Wagner U, Forster T, Fijan A, Bruderer J, et al. HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer. 2003;107:764-72 pubmed
    HER-2/NEU is one of the most frequently amplified oncogenes and a potential therapeutic target in bladder cancer...
  11. Ko S, Na Y, Yoon C, Park J, Kim H, Hur M, et al. The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study. Int J Surg Pathol. 2007;15:98-109 pubmed
    ..In conclusion, our results indicate that expression of c-erbB-2 and p53 did not have any prognostic value in patients with early-stage breast cancer in which axillary lymph node metastasis is absent. ..
  12. Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, et al. Expression of Wnt3 activates Wnt/?-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012;10:1597-606 pubmed publisher
    To understand the mechanisms leading to trastuzumab resistance in HER2-overexpressing breast tumors, we created trastuzumab-insensitive cell lines (SKBR3/100-8 and BT474/100-2)...
  13. Theodoropoulos G, Carraway C, Carraway K. MUC4 involvement in ErbB2/ErbB3 phosphorylation and signaling in response to airway cell mechanical injury. J Cell Biochem. 2009;107:112-22 pubmed publisher
    ..These studies provide a new model for the airway epithelial damage response, in which the MUC4-ErbB2 complex is a key element in the sensor mechanism and phosphorylation of the receptors. ..
  14. Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer. 2014;50:277-89 pubmed publisher
    The discordance in oestrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2) status between primary and recurrent breast cancer is being intensively investigated and a large amount of data ..
  15. Osipo C, Patel P, Rizzo P, Clementz A, Hao L, Golde T, et al. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene. 2008;27:5019-32 pubmed publisher
    ..EGFR)/ErbB-2 tyrosine kinase inhibitor (TKI) increased Notch activity by 2- to 6-fold in SKBr3, BT474 and MCF-7/HER2-18 cells...
  16. Barros Silva J, Leitao D, Afonso L, Vieira J, Dinis Ribeiro M, Fragoso M, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer. 2009;100:487-93 pubmed publisher
  17. Anido J, Scaltriti M, Bech Serra J, Santiago Josefat B, Todo F, Baselga J, et al. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J. 2006;25:3234-44 pubmed
    ..the canonical view contemplates HER receptors restricted to the secretory and endocytic pathways, full-length HER1, HER2 and HER3 have been detected in the nucleoplasm...
  18. Nielsen K, Muller S, Møller S, Schønau A, Balslev E, Knoop A, et al. Aberrations of ERBB2 and TOP2A genes in breast cancer. Mol Oncol. 2010;4:161-8 pubmed publisher
    Copy number changes in TOP2A have frequently been linked to ERBB2 (HER2) amplified breast cancers...
  19. Gianni L, Pienkowski T, Im Y, Roman L, Tseng L, Liu M, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25-32 pubmed publisher
    Studies with pertuzumab, a novel anti-HER2 antibody, show improved efficacy when combined with the established HER2-directed antibody trastuzumab in breast cancer therapy...
  20. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99:628-38 pubmed
    Women with HER2-overexpressing breast cancers have poor prognosis, and many are resistant to the HER2 monoclonal antibody trastuzumab...
  21. Sunami E, Shinozaki M, Sim M, Nguyen S, Vu A, Giuliano A, et al. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res. 2008;10:R46 pubmed publisher
    ..To evaluate epigenetic differences in tumor-related genes relating to ER and HER2/neu status of primary tumors, we examined the promoter methylation status of the promoter region CpG islands of ..
  22. Pradeep C, Zeisel A, Köstler W, Lauriola M, Jacob Hirsch J, Haibe Kains B, et al. Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions. Oncogene. 2012;31:3569-83 pubmed publisher
    ..However, the mechanisms underlying aggressiveness of HER2 (human epidermal growth factor receptor 2)-overexpressing tumors remain incompletely understood...
  23. Al Khattabi H, Kelany A, Buhmeida A, Al Maghrabi J, Lari S, Chaudhary A, et al. Evaluation of HER-2/neu gene amplification by fluorescence in situ hybridization and immunohistochemistry in saudi female breast cancer. Anticancer Res. 2010;30:4081-8 pubmed
    ..This study revealed a significant concordance between FISH results and IHC results. The study also showed that HER2/neu amplification is higher in Saudi patients than other western populations...
  24. Hazan R, Margolis B, Dombalagian M, Ullrich A, Zilberstein A, Schlessinger J. Identification of autophosphorylation sites of HER2/neu. Cell Growth Differ. 1990;1:3-7 pubmed
    b>HER2 or c-erbB-2 is a putative growth factor receptor with sequence homology to the epidermal growth factor receptor...
  25. Half E, Broaddus R, Danenberg K, Danenberg P, Ayers G, Sinicrope F. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer. 2004;108:540-8 pubmed
    The HER-2/neu oncogene encodes a 185 kD protein that is phosphorylated upon ligand binding to other HER/erbB members and regulates cell growth and differentiation...
  26. Yoon S, Lee M, Park S, Moon J, Koh Y, Ahn Y, et al. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. J Biol Chem. 2007;282:26122-31 pubmed
    Expression of the HER2 oncogene is increased in approximately 30% of human breast carcinomas and is closely correlated with the expression of fatty acid synthase (FASN)...
  27. Usha L, Tabesh B, Morrison L, Rao R, Jacobson K, Zhu A, et al. Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts. J Hematol Oncol. 2008;1:12 pubmed publisher
    Amplification of the ERBB2 (Her-2/neu) oncogene, which occurs in approximately 25% of breast carcinomas, is a known negative prognostic factor...
  28. Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Ianzano M, et al. Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor. PLoS ONE. 2012;7:e39626 pubmed publisher
  29. Konecny G, Pauletti G, Untch M, Wang H, Möbus V, Kuhn W, et al. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer. Breast Cancer Res Treat. 2010;120:481-9 pubmed publisher
    In breast cancer, recent studies suggest that the value of HER2 for predicting response to anthracycline-based chemotherapy may be more likely related to the concomitant amplification of the TOP2A gene...
  30. Leary A, Drury S, Detre S, Pancholi S, Lykkesfeldt A, Martin L, et al. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res. 2010;16:1486-97 pubmed publisher
    Acquired endocrine resistance in estrogen receptor (ER)alpha+/human epidermal growth factor receptor 2-negative (HER2-) breast cancer has been associated with modest adaptive increases in HER2, although exactly how aberrant HER2 signaling ..
  31. Matsubara J, Yamada Y, Hirashima Y, Takahari D, Okita N, Kato K, et al. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res. 2008;14:3022-9 pubmed publisher
    ..levels of insulin-like growth factor type 1 receptor (IGF-IR), epidermal growth factor receptor (EGFR), and HER2 expressions have been linked to clinical outcomes in several solid tumors...
  32. Xia W, Bacus S, Husain I, Liu L, Zhao S, Liu Z, et al. Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. Mol Cancer Ther. 2010;9:292-9 pubmed publisher
  33. Garrett J, Olivares M, Rinehart C, Granja Ingram N, Sanchez V, Chakrabarty A, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A. 2011;108:5021-6 pubmed publisher
    ..of HER3 and its output to PI3K/Akt are required for the optimal antitumor effect of therapeutic inhibitors of the HER2 oncogene...
  34. Robidoux A, Tang G, Rastogi P, Geyer C, Azar C, Atkins J, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14:1183-92 pubmed publisher
    ..addition of lapatinib and trastuzumab combined after doxorubicin plus cyclophosphamide treatment in patients with HER2-positive operable breast cancer to determine whether there would be a benefit of dual HER2 blockade in these ..
  35. Zhang D, Tai L, Wong L, Chiu L, Sethi S, Koay E. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics. 2005;4:1686-96 pubmed
    The receptor tyrosine kinase ErbB2 (HER-2/neu) is overexpressed in up to 30% of breast cancers and is associated with poor prognosis and an increased likelihood of metastasis especially in node-positive tumors...
  36. Spears M, Taylor K, Munro A, Cunningham C, Mallon E, Twelves C, et al. In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Res Treat. 2012;132:463-70 pubmed publisher
    b>HER2 overexpression/amplification is linked with poor prognosis in early breast cancer...
  37. Huang T, Wu F, Loeb G, Hsu R, Heidersbach A, Brincat A, et al. Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. J Biol Chem. 2009;284:18515-24 pubmed publisher
    The cell surface receptor tyrosine kinase HER2/neu enhances tumor metastasis...
  38. Kawaguchi Y, Kono K, Mimura K, Mitsui F, Sugai H, Akaike H, et al. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer. 2007;97:494-501 pubmed
    ..The combination of cetuximab and trastuzumab may be useful in the treatment of oesophageal SCC with EGFR and HER-2 expression. ..
  39. Glynn R, Mahon S, Curran C, Callagy G, Miller N, Kerin M. TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer. Oncologist. 2011;16:949-55 pubmed publisher
    To investigate the relationship between human epidermal growth factor receptor (HER)-2/neu and the gene encoding topoisomerase II? (TOP2A) in breast cancer, while elucidating their association with clinicopathological variables...
  40. Schulze W, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol. 2005;1:2005.0008 pubmed
    ..Our results demonstrate that system-wide mapping of peptide-protein interactions sites is possible, and suggest shared and unique roles of ErbB-receptor family members in downstream signaling. ..
  41. Korkaya H, Paulson A, Iovino F, Wicha M. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene. 2008;27:6120-30 pubmed publisher
    ..The HER2 gene is amplified in 20-30% of human breast cancers and has been implicated in mammary tumorigenesis as well as in ..
  42. Wu C, Tu H, Gong N, Chen Y, Liu C, Kao S. The Val allele of HER-2 codon 655 predicts the progression of oral squamous cell carcinoma. Oral Oncol. 2009;45:579-83 pubmed publisher
    ..35-fold higher in patients carrying Val allele. This is the first report demonstrating that the Val allele of HER-2 codon 655 could be an independent predictor for oral carcinoma progression. ..
  43. Sekido Y, Umemura S, Takekoshi S, Suzuki Y, Tokuda Y, Tajima T, et al. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. Int J Oncol. 2003;22:1225-32 pubmed
    ..in genetic events between primary breast cancers and asynchronous metastatic/recurrent lesions, by examining HER2 gene amplification and p53 mutation...
  44. Bourguignon L, Zhu H, Zhou B, Diedrich F, Singleton P, Hung M. Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. J Biol Chem. 2001;276:48679-92 pubmed
    ..analyses indicate that the adaptor molecule, growth factor receptor-bound protein 2 (Grb2) that is bound to p185(HER2) (an oncogene product), is also associated with the CD44v3-Vav2 complex. HA binding to SK-OV-3...
  45. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J. 2004;23:3270-81 pubmed
    ..We conclude that LRIG1 evolved in mammals as a feedback negative attenuator of signaling by receptor tyrosine kinases. ..
  46. Vermeij J, Teugels E, Bourgain C, Xiangming J, In t Veld P, Ghislain V, et al. Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer. 2008;8:3 pubmed publisher
    The status of the EGFR and HER2-neu genes has not been fully defined in ovarian cancer. An integrated analysis of both genes could help define the proportion of patients that would potentially benefit from targeted therapies...
  47. Zaoui K, Benseddik K, Daou P, Salaün D, Badache A. ErbB2 receptor controls microtubule capture by recruiting ACF7 to the plasma membrane of migrating cells. Proc Natl Acad Sci U S A. 2010;107:18517-22 pubmed publisher
    ..By defining the signaling pathway by which ErbB2 allows MT capture and stabilization at the cell leading edge, we provide insights into the mechanism underlying cell motility and steering. ..
  48. Liang K, Esteva F, Albarracin C, Stemke Hale K, Lu Y, Bianchini G, et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell. 2010;18:423-35 pubmed publisher
    We found that the receptor for erythropoietin (EpoR) is coexpressed with human epidermal growth factor receptor-2 (HER2) in a significant percentage of human breast tumor specimens and breast cancer cell lines...
  49. Rafn B, Nielsen C, Andersen S, Szyniarowski P, Corcelle Termeau E, Valo E, et al. ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression. Mol Cell. 2012;45:764-76 pubmed publisher
    ..This work provides a model system for ErbB2-induced breast cancer cell invasiveness, reveals a signaling network that is crucial for invasion in vitro, and defines a specific role and targets for the identified serine-threonine kinases. ..
  50. Jensen J, Knoop A, Laenkholm A, Grauslund M, Jensen M, Santoni Rugiu E, et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol. 2012;23:2034-42 pubmed publisher
    ..This study was conducted to determine the frequency of PIK3CA mutations and human epidermal growth factor receptor-2 (HER2) phosphorylation status (pHER2-Tyr1221/1222) and if PIK3CA, phosphatase and tensin homolog (PTEN), or pHER2 has an ..
  51. Fujii T, Kawahara A, Basaki Y, Hattori S, Nakashima K, Nakano K, et al. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res. 2008;68:1504-12 pubmed publisher
    ..The expression of nuclear YB-1, clinicopathologic findings, and molecular markers [EGFR, HER2, estrogen receptor (ER)alpha, ER beta, progesterone receptor, chemokine (C-X-C motif) receptor 4 (CXCR4), ..
  52. Fang C, Zhao Y, Guo B. MiR-199b-5p targets HER2 in breast cancer cells. J Cell Biochem. 2013;114:1457-63 pubmed publisher
    b>HER2 (ErbB2) has been reported to be overexpressed in 20-30% of breast cancer and confers poor survival because of high proliferation and metastasis rates...
  53. Wang S, Xiang B, Guix M, Olivares M, Parker J, Chung C, et al. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol. 2008;28:5605-20 pubmed publisher
    In HER2-overexpressing mammary epithelial cells, transforming growth factor beta (TGF-beta) activated phosphatidylinositol-3 kinase (PI3K)/Akt and enhanced survival and migration...
  54. Jaiswal B, Kljavin N, Stawiski E, Chan E, Parikh C, Durinck S, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell. 2013;23:603-17 pubmed publisher
    ..Furthermore, we found that anti-ERBB antibodies and small molecule inhibitors effectively blocked mutant ERBB3-mediated oncogenic signaling and disease progression in vivo. ..
  55. Vazquez Martin A, Colomer R, Brunet J, Lupu R, Menendez J. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif. 2008;41:59-85 pubmed publisher
    ..status of either the 1173 Tyr residue of epidermal growth factor receptor (HER1) or the 1248 Tyr residue of HER2, further revealed that FASN-induced Tyr-phosphorylation at approximately 180 kDa region mainly represented that of ..
  56. Meira M, Masson R, Stagljar I, Lienhard S, Maurer F, Boulay A, et al. Memo is a cofilin-interacting protein that influences PLCgamma1 and cofilin activities, and is essential for maintaining directionality during ErbB2-induced tumor-cell migration. J Cell Sci. 2009;122:787-97 pubmed publisher
    ..In summary, these data indicate that Memo also regulates actin dynamics by interacting with cofilin and enhancing its function. ..
  57. Cufí S, Vazquez Martin A, Oliveras Ferraros C, Corominas Faja B, Urruticoechea A, Martin Castillo B, et al. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget. 2012;3:1600-14 pubmed
    ..might allow for the identification of novel autophagy-specific biomarkers for intrinsic (primary) resistance to HER2-targeted therapies...
  58. Sclafani F, Roy A, Cunningham D, Wotherspoon A, Peckitt C, Gonzalez De Castro D, et al. HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. Ann Oncol. 2013;24:3123-8 pubmed publisher
    b>HER2 is an established therapeutic target in breast and gastric cancers. The role of HER2 in rectal cancer is unclear, as conflicting data on the prevalence of HER2 expression in this disease have been reported...
  59. Vernimmen D, Gueders M, Pisvin S, Delvenne P, Winkler R. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. Br J Cancer. 2003;89:899-906 pubmed
    ..In conclusion, our results indicate that different transcriptional and post-transcriptional mechanisms are responsible for the increased levels of erbB-2 transcript and protein in breast and non-breast cancer cells. ..